

Title (en)  
EGF-LIKE NUCLEIC ACIDS AND POLYPEPTIDES AND USES THEREOF

Title (de)  
EGF-ÄHNLICHE NUKLEINSÄUREN UND POLYPEPTIDE UND DEREN ANWENDUNGEN

Title (fr)  
ACIDES NUCLEIQUES ET POLYPEPTIDES ET UTILISATIONS CORRESPONDANTES

Publication  
**EP 1131350 A4 20050504 (EN)**

Application  
**EP 99965849 A 19991119**

Priority  
• US 9927576 W 19991119  
• US 19626998 A 19981119

Abstract (en)  
[origin: WO0029438A1] The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF alpha . The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

IPC 1-7  
**C07K 14/475; C07H 21/04; C12N 15/18; C12N 5/10; C12N 15/09; C12Q 1/68**

IPC 8 full level  
**G01N 33/53** (2006.01); **A61K 31/7088** (2006.01); **A61K 38/00** (2006.01); **A61K 38/22** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 25/18** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/485** (2006.01); **C07K 16/22** (2006.01); **C07K 19/00** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/18** (2006.01); **C12P 21/02** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01)

CPC (source: EP)  
**A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 25/18** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C07K 14/485** (2013.01)

Citation (search report)  
• [PX] WO 9955865 A1 19991104 - GENESIS RES & DEV CORP LTD [NZ]  
• [A] WO 9807736 A1 19980226 - MILLENNIUM BIOTHERAPEUTICS INC [US]  
• See references of WO 0029438A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0029438 A1 20000525; WO 0029438 A9 20010104**; AU 2153500 A 20000605; CA 2351522 A1 20000525; EP 1131350 A1 20010912; EP 1131350 A4 20050504; JP 2002530064 A 20020917

DOCDB simple family (application)  
**US 9927576 W 19991119**; AU 2153500 A 19991119; CA 2351522 A 19991119; EP 99965849 A 19991119; JP 2000582423 A 19991119